Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30914430.
- Also identified by DOI 10.1158/0008-5472.CAN-18-2460 and PMC identifier 6522273.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<i>Dicer1</i> functions as a tumor suppressor in mouse models. In humans, somatic mutations are associated with many cancers in adults, and patients with DICER1 syndrome with <i>DICER1</i> germline mutations are susceptible to childhood cancers. Dicer is phosphorylated by the ERK-MAP kinase pathway and because this pathway is activated in human cancers, we asked whether phosphorylated Dicer1 contributed to tumor development. In human endometrioid cancers, we discovered that phosphorylated DICER1 is significantly associated with invasive disease. To test a direct involvement of Dicer1 phosphorylation in tumor development, we studied mice with phosphomimetic alterations at the two conserved serines phosphorylated by ERK and discovered that a phosphomimetic Dicer1 drives tumor development and dissemination in two independent murine cancer models (<i>KRas<sup>+/LA1</sup></i> and <i>p53<sup>+/-</sup></i> ). Our findings demonstrate that phosphomimetic Dicer1 promotes tumor development and invasion. SIGNIFICANCE: This work highlights the relevance of Dicer1 phosphorylation in mammalian tumor development and dissemination.
Medical subject headings
- Carcinogenesis
- DEAD-box RNA Helicases
- Neoplasms
- Ribonuclease III